海角社区

Chair of Neurosurgery, Roswell Park Cancer Institute Areas of expertise: Neurosurgery, glioblastoma, brain cancer, immunotherapy, cancer vaccines

Dr. Daniela A. Bota is a UCI Health neuro-oncologist who specializes in the treatment of primary and metastatic brain and spinal cord tumors, as well as in the neurological complications of cancers.

Bota is co-director of the UCI Health Comprehensive Brain Tumor Program and is a lead investigator on several clinical trials, including novel treatments using brain tumor vaccines and the use of electrical fields to inhibit the growth of gliomas.

Dr. Ranjit Bindra is a physician-scientist at Yale School of Medicine and Co-Director of the Yale Brain Tumor Center at Smilow Cancer Hospital. In the laboratory, his group recently led a team of four major laboratories at Yale, which reported the stunning discovery that IDH1/2-mutant tumors harbor a profound DNA repair defect that renders them exquisitely sensitive to PARP inhibitors. This work was published in Science Translational Medicine, and Nature, and it has received international attention with major clinical implications Dr. Bindra is now translating this work directly into patients, in four phase I/II clinical trials, including an innovative, biomarker-driven trial specifically targeting the Adolescent/Young Adult (AYA) cancer patient population. In addition, he is lead co-PI of a 35-site, NCI-sponsored Phase II trial testing the PARP inhibitor, olaparib, in adult IDH1/2-mutant solid tumors (NCT03212274). As a biotech entrepreneur he recently co-founded Cybrexa Therapeutics, a Series B round-funded company focused on developing an entirely new class of small molecule DNA repair inhibitors, which directly target the tumor microenvironment. Dr. Bindra received his undergraduate degree in Molecular Biophysics and Biochemistry from Yale University in 1998, and both his MD and PhD from the Yale School of Medicine in 2007. He completed his medical internship, radiation oncology residency, and post-doctoral research studies at the Memorial Sloan-Kettering Cancer Center (MSKCC) in 2012.

Education & Training
Resident
Memorial Sloan-Kettering Cancer Center (2012)
Intern
Memorial Sloan-Kettering Cancer Center (2008)
MD
Yale University School of Medicine (2007)
PhD
Yale University Graduate School (2005)
BS
Yale University (1998)

Dr. Moliterno is a board certified, fellowship trained neurosurgeon specialized in the surgical treatment of all types of primary brain tumors, including gliomas (GBMs, oligodendrogliomas, astrocytomas), meningiomas and acoustic neuromas (vestibular schwannomas), as well as other relatively less common tumor types (medulloblastoma, pineal tumors, intraventricular tumors, epidermoid tumors, etc). She performs the highest volume of brain tumor surgery in the state of Connecticut and routinely cares for patients seeking second or third opinions from afar. Dr. Moliterno has particular expertise in the treatment of complex brain tumors with the safe and effective use of more sophisticated microsurgical techniques, such as functional brain mapping and awake craniotomy for tumors located in highly functioning brain (i.e. speech and motor) areas, as well as those arising along the skull base. Given her skull base surgical specialization, she also routinely performs microvascular decompression for trigeminal neuralgia and hemifacial spasm. Dr. Moliterno is credentialed for performing gamma knife radiosurgery.
Dr. Moliterno serves as the Clinical Director for the Chenevert Family Brain Tumor Center and Chief of Neurosurgical Oncology in the Department of Neurosurgery. She is also the Director of the Multidisciplinary Brain Tumor Board and Precision Brain Tumor Board and the Director for the Neurosurgical Oncology Fellowship Program. She serves as Chair of the Lovemark Foundation Fund at Smilow Cancer Hospital, aimed at providing support for patients with brain tumors.
Dr. Moliterno鈥檚 research interests parallel that of her clinical practice with a bench-to-bedside focus on the clinical implications of the genomics of brain tumors.
She completed her internship and residency training in neurosurgery at Yale New Haven Hospital and clinical fellowship in neurosurgical oncology at the Memorial Sloan-Kettering Cancer Center.

Education & Training
MD
University of Florida College of Medicine (2005)
Fellowship
Memorial Sloan Kettering Cancer Center
Residency
Yale-New Haven Hospital
Internship
Yale-New Haven Hospital

Dr. Omuro is the chief of the Division of Neuro-Oncology and Director of the Yale Brain Tumor Center. He is a graduate and former faculty of the Neuro-Oncology program at Memorial Sloan Kettering Cancer Center in New York. Dr. Omuro is an internationally renowned leader in clinical care and research in the field of brain tumors, having led pivotal research projects and clinical trials to advance the treatment of these difficult cancers. 

Education & Training:
Fellow
Memorial Sloan Kettering Cancer Center (2004)
MD
Sao Paulo School of Medicine (1995)

Timothy Fan laboratory works closely with other basic scientists to evaluate novel drugs and drug delivery strategies for cancer treatment. He has conducted preclinical murine tumor research for over 15 years and facilitated the development of novel drugs and drug delivery strategies for improving cancer therapy. Fan has worked closely with multiple scientific researchers involved in basic and translational cancer investigations, including long-term collaborator Paul Hergenrother, over the past 12 years. Fan has leveraged companion animals as informative tumor model systems to expedite novel drug development, such as the first procaspase-3 activator, PAC-1, which has now successfully advanced to human clinical trials. Fan’s unique training as a scientist and veterinarian allows him to rapidly investigate and translate novel treatment strategies in dogs with spontaneously arising cancers and conduct meaningful comparative oncology research, which may eventually aid in treating cancer in companion animals and human beings.
Fan is a professor of Veterinary Clinical Medicine and serves as the principal investigator of the Comparative Oncology Research Laboratory. Fan is also a core member of the Anticancer Discovery from Pets to People theme at the Carl Woese Institute for Genomic Biology. He received his Doctor of Veterinary Medicine Degree at Virginia-Maryland Regional College of Veterinary Medicine in 1995. He completed a Small Animal Rotating Internship at the University of Illinois in 1996, a Small Animal Internal Medicine Residency at Cornell University in 1998, and a Medical Oncology Fellowship at the University of Illinois in 2000. Fan completed a Ph.D. in Tumor Immunology in 2007, where he investigated the anticancer effects of cytokine manipulation strategies.
Additional Campus Affiliations


Assistant Head, Research & Graduate Studies, Veterinary Clinical Medicine
Director, Veterinary Clinical Trials Center, Veterinary Clinical Medicine
Professor, Veterinary Clinical Medicine
Professor, Veterinary Teaching Hospital
Professor, Pathobiology
Professor, Biomedical and Translational Sciences
Professor, Carl R. Woese Institute for Genomic Biology
Program Leader, Cancer Center at Illinois, Office of the Vice Chancellor for Research and Innovation
Adjunct Professor, Comparative Biosciences